Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Lilian Schwarz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6726-8755; OpenAlex author ID A5043321443. Sources: OpenAlex.

Their work

Papers
13 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 2 papers

Papers 13

  1. Relative dose intensity of gemcitabine-nab-paclitaxel combination as second-line or more in locally advanced or metastatic pancreatic adenocarcinoma. Co-author DOI 10.1016/j.clinre.2025.102583↗
  2. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  3. New Biomarkers to Define a Biological Borderline Situation for Pancreatic Adenocarcinoma: Results of an Ancillary Study of the PANACHE01-PRODIGE48 Trial. Last author DOI 10.1097/sla.0000000000006468↗
  4. Trimodal Peri Operative Prehabilitation for patient with Upper Oesogastric and Pancreatic cancer: study protocol for a multicenter, two- cohort, open-label, si… Co-author DOI 10.21203/rs.3.rs-4488963/v1↗
  5. Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective obs… Co-author DOI 10.1016/j.ejca.2022.01.040↗
  6. Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer. First author DOI 10.3390/cancers13184724↗
  7. Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives. First author DOI 10.1097/cco.0000000000000639↗
  8. Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021. Co-author DOI 10.3390/cancers12123866↗
  9. "Laparoscopic Para-Aortic Lymph Node Sampling" First Approach for Pancreatic Adenocarcinoma as an Oncological Practice. Co-author DOI 10.1089/lap.2018.0775↗
  10. An update on treatment options for pancreatic adenocarcinoma. First author DOI 10.1177/1758835919875568↗
  11. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Co-author DOI 10.1016/j.dld.2018.08.008↗
  12. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODI… Co-author DOI 10.1186/s12885-018-4663-4↗
  13. Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.hoc.2015.04.004↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jean‐Baptiste Bachet · 5 shared papers, 2018–2024 · strength 0.69
  2. Frédéric Di Fiore · 4 shared papers, 2019–2025 · strength 0.68
  3. Déwi Vernerey · 3 shared papers, 2018–2024 · strength 0.54
  4. António Sá Cunha · 4 shared papers, 2018–2024 · strength 0.47
  5. Aurélien Lambert · 3 shared papers, 2019–2022 · strength 0.40
  6. Thierry Conroy · 3 shared papers, 2018–2021 · strength 0.35
  7. Pierre Michel · 2 shared papers, 2018–2025 · strength 0.35
  8. Michel Pierre Ducreux · 2 shared papers, 2019–2021 · strength 0.29
  9. Cindy Neuzillet · 2 shared papers, 2018–2024 · strength 0.29
  10. Adrien Grancher · 1 shared paper, 2025 · strength 0.26
  11. Mehdi El Amrani · 2 shared papers, 2020–2022 · strength 0.24
  12. Anthony Turpin · 2 shared papers, 2020–2022 · strength 0.24
  13. Eva Ester Molina Beltran · 1 shared paper, 2024 · strength 0.23
  14. Jean Pinson · 1 shared paper, 2024 · strength 0.22
  15. Pascal R. Hammel · 2 shared papers, 2018–2020 · strength 0.20
  16. Léo Mas · 1 shared paper, 2020 · strength 0.19
  17. Nicolas Williet · 2 shared papers, 2018–2022 · strength 0.17
  18. Olivier Bouché · 2 shared papers, 2018–2022 · strength 0.17
  19. Fabienne Portales · 2 shared papers, 2018 · strength 0.15
  20. Daniel Pietrasz · 1 shared paper, 2020 · strength 0.13
  21. Christelle d’Engremont · 1 shared paper, 2022 · strength 0.11
  22. Gaël S. Roth · 1 shared paper, 2022 · strength 0.11
  23. Tullio Piardi · 1 shared paper, 2022 · strength 0.11
  24. Mathias Brügel · 1 shared paper, 2022 · strength 0.11
  25. Christophe Borg · 1 shared paper, 2022 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.